Immature oocytes at GV or MI stages were donated by healthy non-diabetic women aged 25–39 years after signed informed consent. The women were undergoing controlled ovarian stimulation (COH) treatments aimed at oocyte cryopreservation or intracytoplasmic sperm injection (ICSI) at the Department of Reproductive Medicine of Karolinska University Hospital. The standard COS treatments and clinical routines have been previously described (Feichtinger et al, 2017 (link)). Briefly, either a long-protocol, using a nasal GnRH agonist (Nafarelin 800 μg daily; Synarela, Pfizer) or buserelin 1200 μg daily; Suprecur, Sanofi), or a short protocol using GnRH antagonist (0.25 mg once daily, SC ganirelix, Fyremadel, Ferring) initiated routinely on the fifth day of COS were conducted. The dose of COS (75–400 IU daily of recombinant follicle stimulating hormone (Gonal-F Merck or hMG Menopur, Ferring) was individualized to patient’s age, menstrual cycle length, antral follicle count and anti-Mullerian hormone levels. Ovarian follicle growth tracking was performed by scheduled transvaginal ultrasound examinations that lead to the planning timepoint for oocyte maturation triggered by administration of recombinant hCG (250 μg SC Ovitrelle; Merck). Oocyte retrieval was carried out by transvaginal ultrasographically-guided follicular puncture 37 h later.
Free full text: Click here
